RBC Capital Maintains Outperform on Pyxis Oncology, Raises Price Target to $7

Benzinga · 3d ago
RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $7.